ZA200701707B - Method of treating hyperphotaemia using lanthanum hydroxycarbonate - Google Patents

Method of treating hyperphotaemia using lanthanum hydroxycarbonate

Info

Publication number
ZA200701707B
ZA200701707B ZA200701707A ZA200701707A ZA200701707B ZA 200701707 B ZA200701707 B ZA 200701707B ZA 200701707 A ZA200701707 A ZA 200701707A ZA 200701707 A ZA200701707 A ZA 200701707A ZA 200701707 B ZA200701707 B ZA 200701707B
Authority
ZA
South Africa
Prior art keywords
hyperphotaemia
treating
lanthanum hydroxycarbonate
hydroxycarbonate
lanthanum
Prior art date
Application number
ZA200701707A
Other languages
English (en)
Inventor
Ferdinando Josephine Christine
Gilmour David
Original Assignee
Shire Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shire Pharmaceuticals Inc filed Critical Shire Pharmaceuticals Inc
Publication of ZA200701707B publication Critical patent/ZA200701707B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/244—Lanthanides; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Inorganic Chemistry (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ZA200701707A 2004-07-27 2007-02-27 Method of treating hyperphotaemia using lanthanum hydroxycarbonate ZA200701707B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US59110504P 2004-07-27 2004-07-27

Publications (1)

Publication Number Publication Date
ZA200701707B true ZA200701707B (en) 2008-10-29

Family

ID=35787449

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200701707A ZA200701707B (en) 2004-07-27 2007-02-27 Method of treating hyperphotaemia using lanthanum hydroxycarbonate

Country Status (14)

Country Link
US (1) US20060153932A1 (xx)
EP (1) EP1708723A4 (xx)
JP (1) JP4869229B2 (xx)
KR (2) KR101072196B1 (xx)
CN (1) CN101018555A (xx)
AU (1) AU2005269362B2 (xx)
BR (1) BRPI0513603A (xx)
CA (1) CA2574450C (xx)
EA (1) EA010980B1 (xx)
MX (1) MX2007001114A (xx)
NO (1) NO20070906L (xx)
NZ (1) NZ552861A (xx)
WO (1) WO2006015055A1 (xx)
ZA (1) ZA200701707B (xx)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060083791A1 (en) 2002-05-24 2006-04-20 Moerck Rudi E Rare earth metal compounds methods of making, and methods of using the same
US20040161474A1 (en) * 2002-05-24 2004-08-19 Moerck Rudi E. Rare earth metal compounds methods of making, and methods of using the same
PL2172205T3 (pl) * 2003-08-26 2015-01-30 Shire Biopharmaceuticals Holdings Ireland Ltd Preparat farmaceutyczny zawierający związki lantanu
CA2583548A1 (en) * 2004-10-15 2006-04-27 Altairnano, Inc. Phosphate binder with reduced pill burden
EP1928349A4 (en) * 2005-08-17 2008-10-01 Altairnano Inc COMPOSITIONS AND METHODS FOR TREATING CHRONIC RENAL FAILURE AND OTHER CONDITIONS IN DOMESTIC ANIMALS
US20070104799A1 (en) * 2005-11-09 2007-05-10 Shire International Licensing B.V. Treatment of chronic kidney disease (CKD) subjects using lanthanum compounds
EP1978808B1 (en) * 2006-01-30 2018-08-29 Panion & BF Biotech Inc. Ferric citrate for reversing, preventing, delaying or stabilizing soft tissue calcification
EP1852695B1 (en) * 2006-05-05 2011-10-26 Shire International Licensing B.V. Assay for lanthanum hydroxy carbonate
US20070259052A1 (en) 2006-05-05 2007-11-08 Shire International Licensing B.V. Assay for lanthanum hydroxycarbonate
KR101830456B1 (ko) * 2010-05-12 2018-02-20 스펙트럼 파마슈티컬즈 인크 란탄 카보네이트 하이드록사이드, 란탄 옥시카보네이트 및 이들의 제조 및 사용 방법
US8263119B2 (en) 2010-12-01 2012-09-11 Shire Llc Capsule formulations containing lanthanum compounds
US8697132B2 (en) 2010-12-01 2014-04-15 Shire Llc Capsule and powder formulations containing lanthanum compounds
GB201501000D0 (en) * 2015-01-21 2015-03-04 Univ Edinburgh Lanthanum thiosulfate and methods of preparation of the same
EP3368078A1 (en) * 2015-10-27 2018-09-05 Medice Arzneimittel Pütter GmbH & Co. KG Nicotinamide for lowering phosphate levels in hyperphosphatemia
US10835461B2 (en) 2015-12-01 2020-11-17 Bae Yong Kim Bio-active material composite, preparing method thereof and cosmetic composition containing the same
KR101684289B1 (ko) 2016-05-17 2016-12-09 한국식품연구원 락토바실러스 sp. KCCM 11826P 균주를 이용한 고인산혈증 예방, 만성 신장질환 치료용 약학조성물 및 건강기능성 식품
US10322409B1 (en) 2018-03-05 2019-06-18 King Fahd University Of Petroleum And Minerals Low temperature hydrothermal method for the preparation of LaCO3OH nanoparticles

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4592082A (en) * 1984-08-10 1986-05-27 The United States Of America As Represented By The United States Department Of Energy Quantitative determination of mineral composition by powder X-ray diffraction
WO1993013758A1 (en) * 1992-01-13 1993-07-22 Pfizer Inc. Preparation of tablets of increased strength
CA2128199C (en) * 1994-07-15 1997-02-04 Bernard Charles Sherman Stable solid pharmaceutical compositions containing enalapril maleate
US5435986A (en) * 1994-08-30 1995-07-25 Industrial Technology Research Institute Method for preparing high purity aluminum hydroxide
GB9506126D0 (en) * 1995-03-25 1995-05-10 Johnson Matthey Plc Pharmaceutical composition and method
GB9720061D0 (en) * 1997-09-19 1997-11-19 Crosfield Joseph & Sons Metal compounds as phosphate binders
US20010014352A1 (en) * 1998-05-27 2001-08-16 Udit Batra Compressed tablet formulation
JP2003508446A (ja) * 1999-09-02 2003-03-04 アコロジックス インコーポレイテッド 血清リン酸レベルを低下させるための方法及び組成物
US6160016A (en) * 1999-12-22 2000-12-12 Wisconsin Alumni Research Foundation Phosphorus binder
GB0015745D0 (en) * 2000-06-27 2000-08-16 Shire Holdings Ag Treatment of bone diseases
DE20221760U1 (de) * 2001-04-23 2007-08-16 Anormed Inc., Langley Verwendung von Seltenerdverbindungen zur Prävention von Nierensteinerkrankung
US7469036B2 (en) * 2002-04-19 2008-12-23 Los Alamos National Security, Llc Analysis of macromolecules, ligands and macromolecule-ligand complexes
WO2003094933A2 (en) * 2002-05-08 2003-11-20 Shire Holding Ag Use of lanthanum for the treatment of hypercalcemia and bone metastasis
US20040161474A1 (en) * 2002-05-24 2004-08-19 Moerck Rudi E. Rare earth metal compounds methods of making, and methods of using the same
US7381428B2 (en) * 2003-08-26 2008-06-03 Shire International Licensing B.V. Stabilized lanthanum carbonate compositions
PL2172205T3 (pl) * 2003-08-26 2015-01-30 Shire Biopharmaceuticals Holdings Ireland Ltd Preparat farmaceutyczny zawierający związki lantanu

Also Published As

Publication number Publication date
CA2574450A1 (en) 2006-02-09
NZ552861A (en) 2010-11-26
US20060153932A1 (en) 2006-07-13
MX2007001114A (es) 2007-07-11
JP4869229B2 (ja) 2012-02-08
BRPI0513603A (pt) 2008-05-13
EP1708723A1 (en) 2006-10-11
NO20070906L (no) 2007-04-23
CA2574450C (en) 2011-07-19
JP2008508297A (ja) 2008-03-21
AU2005269362A1 (en) 2006-02-09
EP1708723A4 (en) 2006-12-20
KR101072196B1 (ko) 2011-10-10
AU2005269362B2 (en) 2010-08-12
EA010980B1 (ru) 2008-12-30
EA200700273A1 (ru) 2007-08-31
KR20070054191A (ko) 2007-05-28
WO2006015055A1 (en) 2006-02-09
KR20090023743A (ko) 2009-03-05
CN101018555A (zh) 2007-08-15

Similar Documents

Publication Publication Date Title
ZA200701707B (en) Method of treating hyperphotaemia using lanthanum hydroxycarbonate
EP1732650A4 (en) COMPOSITION AND METHOD FOR CANCER TREATMENT
GB2423928B (en) Methods and compositions for treating pain
GB2421367B (en) Lighting apparatus and method
EP1715799A4 (en) METHOD FOR TREATING GLAUCOMA
EP1737482A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASES
EP1742590A4 (en) DEVICE AND METHOD FOR TISSUE TREATMENT
IL181922A0 (en) Method for treating vasculitis
HK1121952A1 (en) Methods and compositions for treating conditions
IL177793A0 (en) Method and composition for burned skin
ZA200705459B (en) Treatment method
EP1755394A4 (en) METHOD OF TREATING CANCER
EP1725237A4 (en) ANTI-ALCOHOLIC TREATMENT
ZA200705059B (en) Cancer treatment method
ZA200607115B (en) Permanent treatment method
IL179323A0 (en) Cancer treatment method
EP1742629A4 (en) METHOD FOR TREATING ALCOHOLISM
EP1840948A4 (en) FINE TREATMENT AGENT AND FINE TREATMENT METHOD USING THE SAME
EP1809276A4 (en) PROCESSING PROCESS
IL179359A0 (en) Cancer treatment method
GB0422533D0 (en) Non-aqueous treatment method
EP1856733A4 (en) METHOD FOR LED MICRO PACKAGING AND MICRO PACKAGING
EP1802617A4 (en) CANCER TREATMENT METHOD
GB0403008D0 (en) Composition and method
GB2424579B (en) Method of treating hair